Topiramate chemical structure
Find information on thousands of medical conditions and prescription drugs.

Topiramate

Topiramate (brand name: Topamax®) is an anticonvulsant drug produced by Ortho-McNeil, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also FDA approved for, and now most frequently prescribed for, the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder, although it is not FDA approved for this purpose and such use is somewhat controversial. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

This drug has been investigated for use in treatment of obesity, especially to aid in the reduction of binge eating, and also as a possible treatment for alcoholism. However, these uses are not actively promoted by the manufacturer, and like its use for bipolar disorder, are "off-label" uses. The drug is also used in clinical trials to treat Post Traumatic Stress Disorder. A pilot study suggests that Topiramate is possibly effective against infantile spasm.

Pharmacodynamics

Chemically, Topiramate is a sulfamate-substituted monosaccharide, related to fructose, a rather unusual chemical structure for an anticonvulsant. Topiramate is quickly absorbed after oral use. Most of the drug (70%) is excreted in the urine as unchanged drug. The remainder is extensively metabolized by hydroxylation, hydrolysis, and glucuronidation. Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. Topiramate enhances GABA-activated chloride channels. In addition, Topiramate inhibits excitatory neurotransmission, through actions on kainate and AMPA receptors. There is evidence that Topiramate has a specific effect on GluR5 kainate receptors. It is also an inhibitor of carbonic anhydrase, particular subtypes II and IV, but this action is weak and unlikely to be related to its anticonvulsant actions, but may account for the bad taste and the development of renal stones seen during treatment. Its possible effect as a mood stabilizer seems to occur before anticonvulsant qualities at lower dosages. Topiramate inhibits maximal electroshock and pentylenetetrazol-induced seizures as well as partial and secundarily generalized tonic-clonic seizures in the kindling model, findings predective of a broad spectrum of antiseizure activities clinically.

Side effects

The most common side effects include a change in taste (carbonated beverages, especially diet sodas and beer, taste particularly bad) and feelings of pins and needles in the head and extremities. Less common side effects include cognitive deficiency (particularly word-finding difficulty); grogginess; lethargy; renal stones, impairment of fine motor skills; vision abnormality and transient or permanent vision loss (see below for FDA warning); weight loss; breast pain; abdominal pain; menstrual disorder; taste changes; pharyngitis; sinusitis; diplopia; rash; leukopenia; fatigue; dizziness; insomnia; anxiety; depression; paresthesia; diarrhea; nausea; dyspepsia; constipation; dry-mouth; dysmenorrhea.

Rarely, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance.

The side-effects most frequently leading to discontinuation of therapy with topiramate were :

Read more at Wikipedia.org


[List your site here Free!]


Oral topiramate effective for alcoholism - Patient Oriented Evidence That Matters
From Journal of Family Practice, 9/1/03 by Noble Anderson

Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361:1677-1685.

* PRACTICE RECOMMENDATIONS

Oral topiramate is effective in the treatment of alcohol dependence. Patients taking topiramate consumed less alcohol, had fewer heavy drinking days, and had more days abstinent within a 12-week period. This medication adds a significant adjunct to our current treatment of alcoholism and can be considered for use in treating those alcoholics who desire sobriety.

* BACKGROUND

Alcohol dependence is a fairly common problem seen in family practice. To date, there have been few, if any, effective medications that help patients control or reduce their drinking behavior.

Topiramate is an anticonvulsant that inhibits dopamine release in portions of the brain that may be associated with alcohol's rewarding effects. Carbamazepine, another anticonvulsant, has been shown to decrease drinking among patients in alcohol withdrawal programs. (1) This trial tested the efficacy of treatment with topiramate (in addition to counseling) as a method of reducing alcohol consumption and initiating abstinence.

* POPULATION STUDIED

These researchers enrolled 150 patients with alcohol dependence, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), into the study. They randomly assigned subjects to treatment or placebo groups.

At baseline, the 2 groups did not differ by sex, average number of drinks per day, or age of onset of alcohol abuse. Subjects' average age was 42 years (range, 21-65); 71% were men; 64% white, 32% Hispanic, and 3% African American. Subjects drank an average of 9 drinks per day, with an average 14-year history of alcohol abuse.

Researchers excluded study participants with a positive urine toxicological screen for narcotics, amphetamines, or sedative hypnotics; alcohol withdrawal symptoms; clinically significant physical abnormalities; a history of renal impairment or stones; seizures; or unstable hypertension. They also excluded pregnant or lactating participants and those taking medications affecting alcohol consumption.

Also excluded were study subjects undergoing compulsory treatment for alcohol dependence by an outside agency, subjects treated for alcohol dependence within the 30 days prior to enrollment, or subjects with a current Axis 1 diagnosis other than alcohol or nicotine dependence.

* STUDY DESIGN AND VALIDITY

Patients were randomly assigned to receive escalating doses of either topiramate (maximum of 300 mg/d) or placebo for a period of 12 weeks. Subjects, clinicians, and those assessing treatment outcomes were blind to group assignment; however, it is unclear whether allocation to the groups was concealed.

Patients also underwent brief behavioral counseling administered by trained nurse practitioners. Researchers did not address whether study participants also underwent other behavioral interventions, such as Alcoholics Anonymous meetings. Researchers used an intention-to-treat approach in their statistical analyses.

* OUTCOMES MEASURED

The investigators measured 6 primary outcomes on a weekly basis throughout the 12 weeks of the study. They assessed the number of drinks per day, drinks per drinking day, heavy drinking days (defined as 5 or more drinks for men or 4 or more drinks for women), and number of days abstinent.

They also measured weekly plasma gammaglutamyl transferase (GGT) levels, as an objective measure of alcohol consumption, and a secondary efficacy variable of self-reported craving, which they measured with a 14-item obsessive compulsive drinking scale (validated in a previous study of alcoholism severity). (2)

* RESULTS

Patients taking topiramate had an average of 1 fewer drink per day, both on drinking days and on a daily basis, 15% fewer days of heavy drinking, and approximately 12% more days of abstinence compared with the placebo group. The numbers were even more significant at the end of the study, showing a trend in increasing efficacy over the 12 weeks of follow up. The anticraving effects were also more significant at the end than when averaged over the length of the study. Plasma GGT levels had a statistically significant drop during the study and obsessive-compulsive drinking scale factor scores decreased significantly. All 150 subjects completed the study, and they reported no adverse events.

REFERENCES

(1.) Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17:349-355.

(2.) Moak DH, Anton RF, Latham PK. Further validation of the Obsessive-Compulsive Drinking Scale (OCDS). Relationship to alcoholism severity. Am J Addict 1998; 7:14-23.

Noble Anderson, MD, and M. Norman Oliver, MD, Department of Family Medicine, University of Virginia, Charlottesville. E-mail: nea2p@virginia.edu.

COPYRIGHT 2003 Dowden Health Media, Inc.
COPYRIGHT 2003 Gale Group

Return to Topiramate
Home Contact Resources Exchange Links ebay